A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

PHASE3CompletedINTERVENTIONAL
Enrollment

743

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
DRUG

Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)

Standard chemotherapy

DRUG

Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)

Standard chemotherapy

DRUG

Bendamustine

Standard chemotherapy

DRUG

Rituximab

1400 mg subcutaneously (SC), Day 1 Cycles 2-4

DRUG

Rituximab

375 mg/m2 IV, Day 1 Cycles 1-4

DRUG

Rituximab

375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8

DRUG

Rituximab

1400 mg SC, Day 1 Cycles 5-8

Trial Locations (246)

100

Taipei

852

Hong Kong

883

Kaohsung

1000

Manila

1003

Manila

1097

Budapest

1100

Quezon City

1101

San Salvador

1140

Vienna

1425

Buenos Aires

2031

Randwick

2050

Camperdown

2170

Liverpool

2605

Canberra

3000

Santa Fé

3084

Melbourne

3144

Malvern

3220

Geelong

3400

Corrientes

3500

Krems

3690

Wodonga

4020

Linz

4101

Brisbane

4400

Steyr

Nyíregyháza

5000

Adelaide

5004

Szolnok

5020

Salzburg

5700

Gyula

6000

Perth

Cebu City

6009

Nedlands

6720

Szeged

7000

Hobart

7400

Kaposvár

7500

Holstebro

9000

Aalborg

9024

Győr

10060

Candiolo

10330

Bangkok

10400

Bangkok

10559

Berlin

10700

Bangkok

10967

Berlin

11420

Jakarta

11562

Cairo

11737

Alexandria

12100

Cuneo

12351

Berlin

13581

Berlin

14770

Brandenburg

15236

Frankfurt (Oder)

18055

Rostock

18057

Rostock

18059

Rostock

18107

Rostock

20070

Denizli

20246

Hamburg

21680

Stade

22081

Hamburg

22457

Hamburg

23562

Lübeck

25050

Erzurum

25421

Pinneberg

26121

Oldenburg

26382

Wilhelmshaven

26789

Leer

27568

Bremerhaven

28177

Bremen

29121

Piacenza

30171

Hanover

30625

Hanover

31000

Osijek

32049

Herford

32457

Porta Westfalica

33098

Paderborn

33332

Gütersloh

33604

Bielefeld

33611

Bielefeld

34125

Kassel

35037

Marburg

35392

Giessen

38642

Goslar

39104

Magdeburg

39576

Stendal

40002

Khon Kaen

40161

Bandung

40225

Düsseldorf

40705

Taichung

41239

Mönchengladbach

41944

Daegu

42551

Velbert

43126

Parma

44100

Ferrara

44280

Malatya

44787

Bochum

44791

Bochum

45122

Essen

45239

Essen

45468

Mülheim

45657

Recklinghausen

46236

Bottrop

47441

Moers

48149

Münster

48653

Coesfeld

49076

Osnabrück

49124

Georgsmarienhütte

50200

Chiang Mai

50677

Cologne

51000

Santiago de los Caballeros

52146

Würselen

53127

Bonn

53721

Siegburg

54290

Trier

55041

Lido di Camaiore

55122

Mainz

55284

Yogyakarta

56000

Kuala Lumpur

56727

Mayen

57124

Livorno

58452

Witten

59063

Hamm

59071

Hamm

60111

Surabaya

60389

Frankfurt

60488

Frankfurt

60596

Frankfurt

63450

Hanau

63739

Aschaffenburg

64283

Darmstadt

64295

Darmstadt

65185

Karlstad

65191

Wiesbaden

65549

Limburg

66538

Neunkirchen/Saar

67655

Kaiserslautern

68000

Ampang

68161

Mannheim

70000

Hà Nội

Hochiminh City

70173

Stuttgart

72100

Brindisi

73100

Lecce

73557

Mutlangen

74523

Schwäbisch Hall

75179

Pforzheim

78052

Villingen-Schwenningen

79110

Freiburg im Breisgau

79182

Falun

80804

München

82362

Weilheim

83278

Traunstein

85186

Sundsvall

86150

Augsburg

88100

Catanzaro

88212

Ravensburg

88586

Sabak Bernam

90146

Palermo

90449

Nuremberg

90766

Fürth

93053

Regensburg

93586

Kuching

95445

Bayreuth

96049

Bamberg

97422

Schweinfurt

99817

Eisenach

200143

Craiova

300239

Timișoara

400015

Cluj-Napoca

430031

Baia Mare

500152

Brasov

500326

Brasov

550245

Sibiu

700483

Iași

2520612

Viña del Mar

8380000

Santiago

8420383

Santiago

30150-320

Belo Horizonte

36010-510

Juiz de Fora

37062-770

Varginha

81520-060

Curitiba

86050-190

Londrina

50070-550

Recife

95070-560

Caxias do Sul

93510-250

Novo Hamburgo

97015-373

Santa Maria

09060-650

Santo André

15090-000

São José do Rio Preto

V5G 2X6

Burnaby

V6Z 1Y6

Vancouver

V8R 6V5

Victoria

L8V 5C2

Hamilton

H1T 2M4

Montreal

Unknown

Montería

Giessen

Hong Kong

Auckland

01127

Dresden

01307

Dresden

06110

Halle

07747

Jena

04289

Leipzig

01796

Pirna

07381

Pößneck

04571

Rötha

02763

Zittau

08060

Zwickau

01-010

Guatemala City

01010

Guatemala City

00133

Rome

1186 AH

Amstelveen

1091 AC

Amsterdam

7334 DZ

Apeldoorn

1942 LE

Beverwijk

2906 ZC

Capelle aan den IJssel

9934 JD

Delftzijl

5623 EJ

Eindhoven

4462 RA

Goes

2262 BA

Leidschendam

3045 PM

Rotterdam

2512 VA

The Hague

2566 MJ

The Hague

5022 GC

Tilburg

3582 KE

Utrecht

080814

Panama City

0832-00752

Panama City

0834-02723

Panama City

04001

Arequipa

08006

Cusco

Lima 13

La Victoria, Lima

1449-005

Lisbon

4454-509

Matosinhos Municipality

9500-370

Ponta Delgada

2910-446

Setúbal

3504-509

Viseu

022328

Bucharest

030171

Bucharest

050098

Bucharest

602-739

Busan

03080

Seoul

06591

Seoul

S-413 45

Gothenburg

551_85

Jönköping

SE-71 289

Västerås

06100

Ankara

06200

Ankara

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01724021 - A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | Biotech Hunter | Biotech Hunter